Is Choksi Laborator overvalued or undervalued?

As of 10 October 2025, Choksi Laborator's valuation grade has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued, with a PE ratio of 82.47, an EV to EBITDA ratio of 13.39, and a PEG ratio of 2.92. These ratios suggest that while the company has a high valuation relative to earnings, its growth prospects may justify this premium.
In comparison to its peers, Choksi Laborator stands out with a lower EV to EBITDA ratio than Max Healthcare, which is at 57.79, and Apollo Hospitals at 36.09, despite having a higher PE ratio. This indicates that Choksi may offer better value relative to its earnings potential compared to these competitors. Additionally, the company's remarkable stock performance, with a year-to-date return of 136.58% compared to the Sensex's 5.58%, reinforces the notion that it is undervalued in the current market context.